Maryam N Shahin1, Stephen T Magill2, Cecilia L Dalle Ore1, Jennifer A Viner1, Pamela N Peters3, David A Solomon4, Michael W McDermott1. 1. Department of Neurological Surgery, University of California, San Francisco, CA, 94131, USA. 2. Department of Neurological Surgery, University of California, San Francisco, CA, 94131, USA. Stephen.magill@ucsf.edu. 3. Department of Obstetrics and Gynecology, University of California, San Francisco, CA, 94131, USA. 4. Department of Pathology, University of California, San Francisco, CA, 94131, USA.
Abstract
PURPOSE: Meningiomas are more common in females and 70-80% express the progesterone receptor, raising the possibility that high-dose exogenous estrogen/progesterone exposure, such as occurs during fertility treatments, may increase the risk of developing a meningioma. The goal of this study was to report the incidence of prior fertility treatment in a consecutive series of female meningioma patients. METHODS: A retrospective review (2015-2018) was performed of female patients with meningioma, and those with prior fertility treatment were compared to those without fertility treatment using standard statistical methods. RESULTS: Of 206 female patients with meningioma, 26 (12.6%) had a history of fertility treatments. Patients underwent various forms of assisted reproductive technology including: in vitro fertilization (50.0%), clomiphene with or without intrauterine insemination (34.6%), and unspecified (19.2%). Median follow up was 1.8 years. Tumors were WHO grade I (78.6%) or grade II (21.4%). Patients who underwent fertility treatments presented at significantly younger mean age compared to those who had not (51.8 vs. 57.3 years, p = 0.0135, 2-tailed T-test), and on multivariate analysis were more likely to have multiple meningiomas (OR 4.97, 95% CI 1.4-18.1, p = 0.0154) and convexity/falx meningiomas (OR 4.45, 95% CI 1.7-11.5, p = 0.0021). CONCLUSIONS: Patients in this cohort with a history of fertility treatment were more likely to present at a younger age and have multiple and convexity/falx meningiomas, emphasizing the importance of taking estrogen/progesterone exposure history when evaluating patients with meningioma. Future clinical studies at other centers in larger populations and laboratory investigations are needed to determine the role of fertility treatment in meningioma development.
PURPOSE:Meningiomas are more common in females and 70-80% express the progesterone receptor, raising the possibility that high-dose exogenous estrogen/progesterone exposure, such as occurs during fertility treatments, may increase the risk of developing a meningioma. The goal of this study was to report the incidence of prior fertility treatment in a consecutive series of female meningiomapatients. METHODS: A retrospective review (2015-2018) was performed of female patients with meningioma, and those with prior fertility treatment were compared to those without fertility treatment using standard statistical methods. RESULTS: Of 206 female patients with meningioma, 26 (12.6%) had a history of fertility treatments. Patients underwent various forms of assisted reproductive technology including: in vitro fertilization (50.0%), clomiphene with or without intrauterine insemination (34.6%), and unspecified (19.2%). Median follow up was 1.8 years. Tumors were WHO grade I (78.6%) or grade II (21.4%). Patients who underwent fertility treatments presented at significantly younger mean age compared to those who had not (51.8 vs. 57.3 years, p = 0.0135, 2-tailed T-test), and on multivariate analysis were more likely to have multiple meningiomas (OR 4.97, 95% CI 1.4-18.1, p = 0.0154) and convexity/falx meningiomas (OR 4.45, 95% CI 1.7-11.5, p = 0.0021). CONCLUSIONS:Patients in this cohort with a history of fertility treatment were more likely to present at a younger age and have multiple and convexity/falx meningiomas, emphasizing the importance of taking estrogen/progesterone exposure history when evaluating patients with meningioma. Future clinical studies at other centers in larger populations and laboratory investigations are needed to determine the role of fertility treatment in meningioma development.
Authors: S M Grunberg; M H Weiss; I M Spitz; J Ahmadi; A Sadun; C A Russell; L Lucci; L L Stevenson Journal: J Neurosurg Date: 1991-06 Impact factor: 5.115
Authors: Eriks A Lusis; Bernd W Scheithauer; Anthony T Yachnis; Bernhard R Fischer; Michael R Chicoine; Werner Paulus; Arie Perry Journal: Neurosurgery Date: 2012-11 Impact factor: 4.654
Authors: Elizabeth B Claus; Lisa Calvocoressi; Melissa L Bondy; Margaret Wrensch; Joseph L Wiemels; Joellen M Schildkraut Journal: J Neurosurg Date: 2012-10-26 Impact factor: 5.115
Authors: Cyrus Chargari; Lionel Védrine; Oliver Bauduceau; Sylvestre Le Moulec; Bernard Ceccaldi; Nicolas Magné Journal: Endocr Relat Cancer Date: 2008-07-16 Impact factor: 5.678
Authors: Farshad Nassiri; Justin Z Wang; Karolyn Au; Jill Barnholtz-Sloan; Michael D Jenkinson; Kate Drummond; Yueren Zhou; James M Snyder; Priscilla Brastianos; Thomas Santarius; Suganth Suppiah; Laila Poisson; Francesco Gaillard; Mark Rosenthal; Timothy Kaufmann; Derek S Tsang; Kenneth Aldape; Gelareh Zadeh Journal: Neuro Oncol Date: 2022-05-04 Impact factor: 13.029
Authors: Francesco Maiuri; Giuseppe Mariniello; Teresa Somma; Elia Guadagno; Sergio Corvino; Serena Pagano; Valentina Orlando; Marialaura Del Basso De Caro Journal: Front Oncol Date: 2020-12-11 Impact factor: 6.244